Stoke Therapeutics
Bedford
About Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $360.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2024)
- Ticker: nasdaq:STOK
- Website: stoketherapeutics.com
- Phone: 781-430-8200
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/stoke-therapeutics-33586 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.